Graphite Corp. (GRPH) Announces CFO Departure Jun 23, 2023 07:01AM
Graphite Bio Announces Departure of Chief Financial Officer Jun 23, 2023 07:00AM
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results Mar 20, 2023 04:05PM
Graphite Corp. (GRPH) Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel Jan 5, 2023 04:06PM
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease Jan 5, 2023 04:05PM


Dec 11, 2022 10:00AM Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
Nov 21, 2022 08:00AM Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
Nov 9, 2022 04:05PM Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
Nov 3, 2022 09:05AM Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
Oct 11, 2022 08:00AM Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
Sep 6, 2022 08:00AM Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
Aug 11, 2022 04:05PM Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
Aug 11, 2022 08:16AM Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease